Personalized, Autologous Neoantigen-Specific T Cell Therapy in Metastatic Melanoma: A Phase I Trial

Researchers designed BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, and tested this in a 3 + 3 dose-finding study with two dose levels in patients with locally advanced or metastatic melanoma, disease progression after immune checkpoint blockade, measurable disease and, where appropriate, BRAF-targeted therapy.